890850O
Avanti
18:1 DAP
Avanti Research™ - A Croda Brand
Synonym(s):
1,2-dioleoyl-3-dimethylammonium-propane (DODAP)
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C41H77NO4
CAS Number:
Molecular Weight:
648.05
UNSPSC Code:
12352211
NACRES:
NA.25
Recommended Products
form
liquid
packaging
pkg of 2 × 100 mg (890850O-200mg)
pkg of 1 × 25 mg (890850O-25mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
lipid type
cationic lipids
transfection
shipped in
dry ice
storage temp.
−20°C
SMILES string
[H]C(CN(C)C)(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O
General description
18:1 DAP is a cationic lipid, used for the preparation of cationic liposomes.
Application
18:1 DAP is suitable for:
- as a component of lipid bilayers
- in the formulation of stable nucleic acid lipid vesicles
- in the preparation and physicochemical characterization of antisense oligodeoxyribonucleotide (ODN)-containing folate (FA)-targeted or non-targeted liposomes
Packaging
5 mL Clear Glass Sealed Ampule (890850O-200mg)
5 mL Clear Glass Sealed Ampule (890850O-25mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Storage Class
10 - Combustible liquids
wgk_germany
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Transferrin-conjugated SNALPs encapsulating 2?-O-methylated miR-34a for the treatment of multiple myeloma
Scognamiglio I, et al.
BioMed Research International, 2014 (2014)
Preparation and in-vitro evaluation of an antisense-containing cationic liposome against non-small cell lung cancer: a comparative preparation study
Saffari M, et al.
Iranian Journal of Pharmaceutical Research : IJPR, 12(Suppl), 3-3 (2013)
Nonequilibrium adhesion patterns at lipid bilayer junctions
Parthasarathy R, et al.
The Journal of Physical Chemistry B, 108(2), 649-657 (2004)
Qiang Cheng et al.
Nature nanotechnology, 15(4), 313-320 (2020-04-07)
CRISPR-Cas gene editing and messenger RNA-based protein replacement therapy hold tremendous potential to effectively treat disease-causing mutations with diverse cellular origin. However, it is currently impossible to rationally design nanoparticles that selectively target specific tissues. Here, we report a strategy
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service